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Abstract
Adjusting drug therapy to the individual, a common approach in clinical practice, has evolved from
1) dose adjustments based on clinical effects to 2) dose adjustments made in response to drug levels
and, more recently, to 3) dose adjustments based on deoxyribonucleic acid (DNA) sequencing of
drug-metabolizing enzyme genes, suggesting a slow drug metabolism phenotype. This development
dates back to the middle of the 20th century, when several different drugs were administered on
the basis of individual plasma concentration measurements. Genetic control of drug metabolism
was well established by the 1960s, and pharmakokinetic-based individualized therapy was in use by
1973.
Patterns of drug prescription
Despite tremendous advances in the science and technol-
ogy of drug development, as well the emergence of guid-
ance and consensus building among scientists, many
clinicians, pharmacists, and consumers remain unin-
formed regarding the scientific basis of establishing
bioequivalence, the generic-drug approval process, and
the issues related to individualizing therapy in general
[7,8]. The consequence may be drug dosing errors: over-
dosing or underdosing of drugs, resulting in the occur-
rence of harmful effects or the nonoccurrence of the
expected treatment benefit.
Recent information [9] indicates that doctors are not con-
sistently prescribing proven treatments at recommended
doses, and at times they are not prescribing proven treat-
ments at all. A decrease in dose may decrease the efficacy
(relative risk reduction [RRR]) of therapy and thereby
decrease the treatment's net benefit. Not prescribing an
agent will effectively nullify the potential benefit to indi-
viduals, and when repeated frequently enough, failure to
prescribe the agent will significantly decrease the benefit
to the population as a whole. At other times, doctors tend
to prescribe a drug more generally than clinical trials dic-
tate. The treatment of a population with lower outcome
prevalence (OP) decreases net benefit and may lead to
harm. Overdosing may increase treatment-related harm,
and underdosing may erode efficacy; both will result in
diminished treatment benefits. Finally, noncompliance
on the part of the patient may lead to a decrease in efficacy
and a requisite decrease in net treatment benefit. If a
patient reduces the dose without totally eliminating the
drug, the risk of non-dose-related side effects of treatment
may remain.
The relationship between the terms mentioned above,
which govern treatment success, can be expressed mathe-
matically as follows [10-12]:
Net Benefit = RRR * OP - Harm
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of observations that expand our understanding of the
benefits and risks of treatment.
The difficulties in drug prescription that are mentioned
above are not related to the physicians' training or experi-
ence but result instead from difficulties in relying with
confidence on label claims of efficacy, safety, and inter-
changeable use of new drugs "within class." The common
denominator among these problems seems to be an insuf-
ficiently well crystallized knowledge base regarding the
proper use and interpretation of general terms such as
equivalence/similarity, pharmaceutical equivalence/therapeutic
equivalence, and bioequivalence/bioavailability. Problems are
further compounded by the increasing use of generic
drugs and the interpretation of such terms as prescribability
and switchability.
Term definitions
Bioavailability (BA) indicates a measurement of the rate
and amount of therapeutically active drug that reaches the
general circulation and its presumed site of action [13].
Bioequivalent drug products (BE)
Bioequivalence is the absence of a significant difference in
the rate at which, and the extent to which, the active
ingredients in pharmaceutical equivalents become availa-
ble at the site of drug action in the body when adminis-
tered under similar experimental conditions in an
appropriately designed study. A product may also be con-
sidered bioequivalent to an innovator product if (a) the
difference in rate of drug absorption between the two
products is intentional and (b) no significant difference is
found in the extent of absorption of the two products
when they are evaluated under similar experimental con-
ditions [13-17].
Bioequivalence requirement refers to a requirement,
imposed by the Food and Drug Administration (FDA), of
in vitro and/or in vivo testing of specified drug products
that must be satisfied as a condition of marketing [17].
Pharmaceutical alternatives are drug products that contain
the identical therapeutic moiety, or its precursor, but not
necessarily in the same amount or dosage form as the
same salt or ester. Each such drug product individually
meets either the identical or its own respective compen-
dial or other applicable standards of identity, strength,
quality, and purity, including potency and, where applica-
ble, content uniformity, disintegration times, and/or dis-
solution rates [17].
Pharmaceutical equivalence
To be considered pharmaceutically equivalent, two drug
products must (a) contain identical amounts of the same
active ingredients in the same dosage form, (b) be formu-
lated to meet the same compendial or other applicable
standards of quality and purity, and (c) generally be
labeled for the same indications. However, pharmaceuti-
cal equivalents may differ in the excipients (e.g., flavors,
preservatives) that they contain, as well as in their shape,
scoring, packaging, and in certain circumstances, their
labeling [17].
Average bioequivalence involves assessment of pharmacok-
inetic parameters such as area under the curve (AUC) and
peak concentration (Cmax), as well as calculation of a
90% confidence interval for the ratio of the averages of
these parameters for the two products that are compared,
usually a test product (T) against a reference product (R).
The calculated confidence interval should fall within a
conventionally established BE limit of 80% to 125% for
the ratio of the product averages [18]. The clinical judg-
ment underlying this BE limit is that a test product with
BA measures outside this range would be denied market
access. However, in specified circumstances, clinical judg-
ment permits widening or narrowing of the BE limit (e.g.,
Basic relationshipsFigure 1
Basic relationships. Net benefit is plotted as a function of 
outcome prevalence. The line represents the relationship 
with the assumption of a relative risk reduction of 30% and 
treatment harm of 0%. The line is the maximum net benefit 
that can be attained at any given outcome prevalence. The x-
intercept, or benefit threshold, represents the outcome prev-
alence at which net benefit will accrue to individuals and the 
population as a whole. The point of maximum benefit occurs 
when the outcome prevalence is 100%; at this point, if harm 
is absent, the net benefit or efficiency of treatment equals the 
relative risk reduction or efficacy of that treatment. Benefit 
decreases proportionately as a function of outcome 
prevalence.Page 2 of 7
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drug products).
Since the implementation of the FDA Bioavailability and
Bioequivalence Requirements in 1977, the assessment of
bioequivalence has been a subject of continuous debate
[16,20-22]. This controversy has led to modifications in
the bioavailability/bioequivalence regulations and guide-
lines. Despite these modifications, the process of assessing
bioequivalence continues to evolve as scientific consensus
emerges on many of the issues driving the debate [23].
The average BE reflects comparison of population aver-
ages and therefore fails to assess the subject-by-formula-
tion interaction variance (i.e., the variation of the averages
in particular individuals). In contrast, the newer population
and individual approaches reflect differences in the objec-
tives of BE testing at various stages of drug development.
These differences are embodied in the concepts of prescrib-
ability and switchability (interchangeability) [19-22].
These concepts underscore the difference between the
population and individual bioequivalence approaches.
Population bioequivalence assesses total variability of the
measure in the population, and it becomes important
when physicians are initially prescribing a medication and
they need to rely on the average performance of the drug
product [24]. In contrast, the most important considera-
tion for individual bioequivalence rests on the assurance
that products deemed bioequivalent can be used inter-
changeably in the target population (i.e., they exhibit
switchability) [25]. In addition to the comparison of aver-
ages, the individual bioequivalence approach compares
within-subject variabilities and assesses subject-by-formu-
lation interaction. It offers flexible equivalence criteria
based on the individual therapeutic window and variabil-
ity of the reference drug product. Furthermore, it allows
scaling criteria for highly variable/narrow-therapeutic-
range drugs and promotes the use of subjects from the
general population in bioequivalence studies.
Prescribability refers to the clinical setting in which a prac-
titioner prescribes a drug product to a patient for the first
time. In this setting, the prescriber relies on the under-
standing that the average performance of the drug product
has been well characterized and relates in some definable
way to the safety and efficacy information from clinical
trials. Switchability refers to the setting in which a practi-
tioner transfers a patient from one drug product to
another. This situation arises with generic substitution, as
well as with postapproval changes by an innovator or a
generic firm in the formulation and/or manufacture of a
drug product. Under these circumstances, both the pre-
scriber of the drug and the patient should be assured that
the newly administered drug product will yield safety and
efficacy comparable to that of the product for which it is
being substituted. However, such a switch may, in fact,
occur without the patient's or clinician's knowledge, and
this concern is addressed in equivalence studies designed
to minimize the risk to the patient in both situations.
Although average bioequivalence is the recommended
parameter for most bioequivalence studies, the current
FDA guide titled Statistical Approaches to Establishing
Bioequivalence [26] recommends that population and
individual bioequivalence also be evaluated in some
cases. Understanding of this process is enhanced by the
outline in Figure 2, which illustrates the classical expo-
sure-response relationship that might assist in adjusting
dosages and dosing regimens in the presence of influences
on pharmacokinetics (PK) by demographic factors (e.g.,
age, gender), intrinsic factors (e.g., impaired organ
Exposure-response relationshipsFigure 2
Exposure-response relationships. Relationships between (1) 
drug substance and drug product, (2) exposure expressed as 
dose or systemic exposure on log scale, and (3) positive (effi-
cacy) or negative (toxicity) outcomes. These outcomes may 
be measured by clinical end points, surrogate endpoints, or 
biomarkers. The relationships between exposure and out-
comes define the optimal dose and therapeutic window. The 
term change introduces the concept of equivalence in out-
comes before or after a specified change (eg, generic substi-
tution, postapproval manufacturing change). CMC, 
Chemistry, manufacturing, and controls; BA/BE, bioavailabil-
ity and bioequivalence; PK, pharmacokinetics; PD, 
pharmacodynamics.Page 3 of 7
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tion, food intake).
The outcomes (clinical benefit, reflecting the "response"
component of the relationship), can be measured as clin-
ical or surrogate endpoints or as biomarkers. The relation-
ship between exposure and outcomes, expressed as dose-
or concentration-response curves that have efficacy and
toxicity levels at their extremes, define the optimal dose
and the therapeutic window [27]. Theoretically, these
curves should be generated in different individuals for
developing prescribability criteria, and in the same indi-
viduals for developing switchabiliy criteria.
Premarketing risk-benefit assessment
The approach described above is a simplified framework
of successive steps to be taken in phases I and II of the
development of any drug, with the aim of generating data
for drug labeling (i.e., data on dose-response [effective-
ness and toxicity] relations of the new agent and how
these depend on patient characteristics). The dose regi-
men of such a new agent, explored and established
through phases I and II, is to be demonstrated in phase III
as "safe and effective" for the claimed indication. Proper
study design and research methodology, as well as appro-
priate statistical analysis, should be applied to ensure that
the drug's effectiveness can be substantiated. Further, the
outcome derived from two such randomized clinical trials
should document that the estimate of the true treatment
effect favors the new drug over the reference drug and that
the toxicity of the new agent does not exceed acceptable
limits. In other words, a first risk/benefit assessment
would favor the new drug.
Having come that far, a question justifiably arises: what
logic leads to the conclusion that the new drug is likely to
be effective in future patients? That is, are the treatment
benefits generalizable to an actual clinical population?
The question is extended to external validity, meaning the
extent to which the conclusions of a study would hold
true for other persons, in other places and at other times.
Examples from most therapeutic areas indicate that
approved drugs may not work as expected when applied
in broad community populations, in real-world settings,
and among diverse practitioners operating under real-
world constraints [28]. In such instances, years of effort
and huge investments fail to meet the intent of providers,
the expectations of consumers, or the demands of health-
care payers.
Conventionally, the dose-response trials mentioned
above, exploring the behavior of biomarkers both cross-
sectionally between individuals treated with different
doses of an agent, and longitudinally within individuals
as doses (or concentrations) change with time, supply the
necessary information on the drug's pharmacologic action
(the so-called empiric confirmation at a conventional α
level). However, despite all their methodological rigor-
ousness, these trials may not entirely eliminate factors
that influence bioavailability in earlier development
stages and internal validity in later-phase studies (rand-
omized controlled trials [RCTs]).
Bioavailability may be influenced by
• Patient-related factors, such as concurrent diseases, dif-
ferences in first-pass metabolism, interactions with con-
comitant medications, diet, circadian biorhythms, the
influence of fed-versus fasted-state physiologic condi-
tions, and gastrointestinal factors (e.g., pH, motility,
blood flow, bacterial flora) [29-32].
• Product-related factors, such as: physical and chemical
properties of the drug (e.g., solubility, degree of ioniza-
tion, crystalline forms, chemical form, isomers), as well as
variables related to manufacturing, formulation, or both
(e.g., coatings, compression force, particle size, presence
or absence of excipients) [30-33].
To control for as many variables as possible, most
bioequivalence trials are conducted with healthy volun-
teers as subjects, [19,34,35] and in real patients only in
circumstances wherein the use of volunteers would be
unethical (e.g., tests with cytotoxic drugs) or when assess-
ment of bioequivalence is based on pharmacodynamic
and/or clinical end points [35].
The causal confirmation is much more complex than the
empiric confirmation, even if the drug's previously estab-
lished pharmacologic action is believed to ensure that the
drug has the same intrinsic property that alters the clinical
outcome – in the RCT patients – in a similar way and to a
similar extent as in the previous patients.
A number of other causes, however, may interfere in the
conduct phase of an RCT. These causes include
• Confounding – a distortion of an association between
an exposure and disease brought about by extraneous
factors.
• Interaction – the interdependent operation of two or
more factors that produce an unanticipated effect.
• Transience – an idiosyncratic property of a drug that dis-
plays its expected pharmacologic property when tested in
one batch, but not in others.
Many of the specific design and analysis features applied
to RCTs (e.g., blinding, randomization, intention-to-treatPage 4 of 7
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founding is minimized or eliminated. The same does not
apply in the case of transience or interaction, for which
independent evidence is needed to eliminate those
possibilities.
Highly variable drugs
Drugs that tend to exhibit high degrees of variability in
their pharmacokinetic profiles are known to complicate
the assessment of bioequivalence [22,36,37]. This is, at
least in part, a function of the high intrasubject variability
(previously defined as greater than 30%) of the drug or
drug product [22]. Examples of such drugs are propaf-
enone immediate release, verapamil, and nadolol.
Narrow-therapeutic-index drugs
Small changes in systemic concentration of such drugs can
lead to marked changes in pharmacodynamic responses
[19-22]. A broader term for the narrow-therapeutic-index
drugs is "critical-dose drugs." Characteristically, these
agents require blood-level monitoring, need to be dosed
on the basis of body weight or other individualized
parameters, display serious clinical consequences if over-
dosing or underdosing occurs, and manifest a steep dose-
response relationship [38].
A typical drug in this category is warfarin, which is widely
used for its anticoagulant properties. For the most part,
metabolism of S-warfarin occurs by means of the gene
CYP2C9 [39]. Inhibition of this isoform results in several
clinically important drug interactions. Fluconazole, met-
ronidazole, miconazole, and amiodarone are a few exam-
ples of the many drugs that profoundly inhibit S-warfarin
metabolism and produce marked increases in pro-
thrombin time (PT) measurements [40-43]. A multitude
of endogenous and exogenous factors may contribute
alone or in combination to either increasing or decreasing
PT ratio or the INR response [44].
Factors that increase PT ratio or international normalized
ratio (INR) response include:
Endogenous factors: 11
Exogenous factors: 117 specific drugs and 49 different
classes of drugs
Factors that decrease PT ratio or INR response include:
Endogenous factors: 5
Exogenous factors: 42 specific drugs and 24 different
classes of drugs
Physician surveys have indicated that most clinicians
favor more rigid bioequivalence guidelines for these types
of drugs [8]. Others have recommended that the
bioequivalence requirement for these agents be based on
intrasubject variability, as well as the pharmacokinetic-
pharmacodynamic relationship. Although the FDA has
not modified the bioequivalence guidelines for critical-
dose drugs, the Canadian regulatory authority, Health
Canada, has narrowed the CI requirement for these drugs
to 90% to 110%. For prescribability, the current require-
ments may be adequate for all drugs, including those with
a narrow therapeutic index. However, some clinicians
have expressed concerns about switchability [7,39]. Sev-
eral reports suggest that once a patient has been carefully
titrated on a narrow-therapeutic-index drug, the formula-
tion should not be switched [7,8]. The same might be true
of warfarin.
Drug products suspected of having bioequivalence prob-
lems are listed in the Orange Book (Approved Drug Prod-
ucts with Therapeutic Equivalence Evaluations) [45]. Such
drugs may exhibit a narrow therapeutic index or solubility
problems, or they may be poorly absorbed or unstable in
gastrointestinal fluids [33]. Among clinicians there seems
to be widespread concern that even small changes in the
bioavailability of drugs' active ingredients might lead to
significant changes in the efficacy or safety of those prod-
ucts [7,8,38].
The concept of risk and its application to drug 
development
In light of serious concerns about risks incurred from
using medical products, a variety of public and private
agencies involved in health care are dedicating more
attention to examining the current system of managing
these risks. The main goal is to focus on the costs and
value of better data concerning the incidence and causes
of injuries from medical products and the roles of all
stakeholders in risk management.
The FDA has issued a concept paper [46] presenting pre-
liminary thoughts on risk issues, including:
• Important risk assessment concepts.
• Generation and acquisition of safety data during prod-
uct development.
• Analysis and presentation of safety data in an applica-
tion for approval.
Risk assessment, defined as the process of identifying, esti-
mating, and evaluating the nature and severity of risks
associated with a product, should be continuous through-
out the life cycle of any product, whereas the process ofPage 5 of 7
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safe use of a product by reducing risk.
With regard to the current trend toward systemic risk con-
frontation, the FDA, Center for Drug Evaluation and
Research (CDER), and Center for Biologics Evaluation
and Research (CBER) appear ready to develop and final-
ize, by fall 2004, guidance documents regarding risk
assessment, clinical pharmacovigilance, and risk manage-
ment. Table 1 highlights the components of a risk man-
agement system (RMS).
Conclusions
Determining the optimal initial dosage regimen (prescrib-
ability) and maintaining safety and efficacy outcomes
when the regimen is changed in some way (switchability)
demand careful decision making in the application of
equivalence approaches. These approaches must be
applied differently during the three phases of the drug
development process, and the knowledge-base that is
derived from this process must be transferred to and uti-
lized by physicians and pharmacists to assist them in pre-
scribing and dispensing medicines to patients. Consistent
and appropriate management of equivalence approaches
supports good assessment, management, and communi-
cation about risks associated with a therapeutic product,
as expressed in product labeling, as well as in specifica-
tions and standards that control the quality of a therapeu-
tic product in the marketplace.
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